Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529

Nature Chemical Biology

Volumn 13, Issue 10, 2017, Pages 1115-1122

  Pancera, Marie ^a   Lai, Yen Ting ^a   Bylund, Tatsiana ^a   Druz, Aliaksandr ^a   Narpala, Sandeep ^a   O'Dell, Sijy ^a   Schön, Arne ^b   Bailer, Robert T ^a   Chuang, Gwo Yu ^a   Geng, Hui ^a   Louder, Mark K ^a   Rawi, Reda ^a   Soumana, Djade I ^a   Finzi, Andrés ^c   Herschhorn, Alon ^d   Madani, Navid ^d   Sodroski, Joseph ^d   Freire, Ernesto ^b   Langley, David R ^e   Mascola, John R ^a   McDermott, Adrian B ^a   Kwong, Peter D ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; GLYCOPROTEIN GP 120; SOLVENT; TEMSAVIR; BMS-378806; BMS-626529; GLYCOPROTEIN GP 41; MOLECULAR LIBRARY; PIPERAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ALLOSTERISM; ANTIGENICITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS NEUTRALIZATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; MOLECULAR LIBRARY; MOLECULAR MODEL; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; MODELS, MOLECULAR; PIPERAZINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 85030974417     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2460     Document Type: Article

References (60)

1. Lima, V.D. et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 21, 685-692 (2007).
2. Marcus, J.L. et al. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J. Acquir. Immune Defic. Syndr. 73, 39-46 (2016).
3. Vittinghoff, E. et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J. Infect. Dis. 179, 717-720 (1999).
4. Kwon, Y.D. et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat. Struct. Mol. Biol. 22, 522-531 (2015).
5. Wyatt, R. & Sodroski, J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884-1888 (1998).
6. Munro, J.B. et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346, 759-763 (2014).
7. Wild, C., Greenwell, T. & Matthews, T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 9, 1051-1053 (1993).
8. Oldfield, V., Keating, G.M. & Plosker, G. Enfuvirtide: a review of its use in the management of HIV infection. Drugs 65, 1139-1160 (2005).
9. Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
10. Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861 (2010).
11. Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412 (2012).
12. Muster, T. et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 68, 4031-4034 (1994).
13. Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108-1121 (2016).
14. Kwong, P.D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-659 (1998).
15. Zhao, Q. et al. Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339, 213-225 (2005).
16. LaLonde, J.M. et al. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J. Med. Chem. 55, 4382-4396 (2012).
17. Madani, N. et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16, 1689-1701 (2008).
18. Huang, C.C. et al. Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure 13, 755-768 (2005).
19. Wang, T. et al. Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2- (R)-methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46, 4236-4239 (2003).
20. Guo, Q. et al. Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions. J. Virol. 77, 10528-10536 (2003).
21. Ho, H.T. et al. Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events. J. Virol. 80, 4017-4025 (2006).
22. Lin, P.F. et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. USA 100, 11013-11018 (2003).
23. Wang, T. et al. Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 5. An evolution from indole to azaindoles leading to the discovery of 1-(4-benzoylpiperazin-1-yl)-2-(4,7-dimethoxy-1H-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (BMS-488043), a drug candidate that demonstrates antiviral activity in HIV-1-infected subjects. J. Med. Chem. 52, 7778-7787 (2009).
24. Kadow, J., Wang, H.G. & Lin, P.F. Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: an emerging opportunity for drug development. Curr. Opin. Investig. Drugs 7, 721-726 (2006).
25. Nowicka-Sans, B. et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob. Agents Chemother. 56, 3498-3507 (2012).
26. Brown, J. et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J. Pharm. Sci. 102, 1742-1751 (2013).
27. Lalezari, J.P. et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV 2, e427-e437 (2015).
28. Nettles, R.E. et al. Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects. J. Infect. Dis. 206, 1002-1011 (2012).
29. Ray, N. et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J. Acquir. Immune Defic. Syndr. 64, 7-15 (2013).
30. Zhou, N. et al. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J. Antimicrob. Chemother. 69, 573-581 (2014).
31. Pancera, M. et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 514, 455-461 (2014).
32. Sanders, R.W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013).
33. Si, Z. et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc. Natl. Acad. Sci. USA 101, 5036-5041 (2004).
34. Walker, L.M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466-470 (2011).
35. Huang, J. et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515, 138-142 (2014).
36. Strong, M. et al. Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103, 8060-8065 (2006).
37. Madani, N. et al. Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J. Virol. 78, 3742-3752 (2004).
38. Zhou, N. et al. In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043. Antimicrob. Agents Chemother. 55, 729-737 (2011).
39. Schader, S.M. et al. HIV gp120 H375 is unique to HIV-1 subtype CRF01-AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug. Antimicrob. Agents Chemother. 56, 4257-4267 (2012).
40. Herschhorn, A. et al. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat. Chem. Biol. 10, 845-852 (2014).
41. Herschhorn, A. et al. Release of gp120 restraints leads to an entry-competent intermediate state of the HIV-1 envelope glycoproteins. MBio 7, e01598-16 (2016).
42. Pancera, M. et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. USA 107, 1166-1171 (2010).
43. Langley, D.R. et al. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins 83, 331-350 (2015).
44. Kong, R., Tan, J.J., Ma, X.H., Chen, W.Z. & Wang, C.X. Prediction of the binding mode between BMS-378806 and HIV-1 gp120 by docking and molecular dynamics simulation. Biochim. Biophys. Acta 1764, 766-772 (2006).
45. Teixeira, C., Serradji, N., Maurel, F. & Barbault, F. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Eur. J. Med. Chem. 44, 3524-3532 (2009).
46. Li, L., Chen, H., Zhao, R.N. & Han, J.G. The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations. J. Mol. Model. 19, 905-917 (2013).
47. Liu, Q. et al. Quaternary contact in the initial interaction of CD4 with the HIV-1 envelope trimer. Nat. Struct. Mol. Biol. 24, 370-378 (2017).
48. Guttman, M. et al. CD4-induced activation in a soluble HIV-1 Env trimer. Structure 22, 974-984 (2014).
49. Da, L.T., Quan, J.M. & Wu, Y.D. Understanding the binding mode and function of BMS-488043 against HIV-1 viral entry. Proteins 79, 1810-1819 (2011).
50. Shrivastava, I.H., Wendel, K. & LaLonde, J.M. Spontaneous rearrangement of the β20/β21 strands in simulations of unliganded HIV-1 glycoprotein, gp120. Biochemistry 51, 7783-7793 (2012).
51. Li, M. et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108-10125 (2005).
52. Seaman, M.S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439-1452 (2010).
53. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
54. Weiss, M.S. Global indicators of X-ray data quality. J. Appl. Crystallogr. 34, 130-135 (2001).
55. Karplus, P.A. & Diederichs, K. Linking crystallographic model and data quality. Science 336, 1030-1033 (2012).
56. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
57. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
58. Adams, P.D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
59. Davis, I.W., Murray, L.W., Richardson, J.S. & Richardson, D.C. MOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes. Nucleic Acids Res. 32, W615-W619 (2004).
60. DeLano, W.L. The PyMOL Molecular Graphics System (DeLano Scientific, San Carlos, CA, 2002).